Genocea Reports Fourth Quarter and Full-Year 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Genocea Biosciences (GNCA) PT Lowered to $2 at Cowen
February 15, 2018 3:00 PM ESTCowen lowered its price target on Genocea Biosciences (NASDAQ: GNCA) to $2.00 (from $5.00) while maintaining a Outperform rating.
Analyst Phil Nadeau commented, "Genocea reported Q4 financials including a net loss of $11MM and a pro-forma cash balance of $64MM. Meanwhile, lead... More
